Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants


Griffin M. P. , Yuan Y., Takas T., Domachowske J. B. , Madhi S. A. , Manzoni P. , ...Daha Fazla

NEW ENGLAND JOURNAL OF MEDICINE, cilt.383, ss.415-425, 2020 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 383 Konu: 5
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1056/nejmoa1913556
  • Dergi Adı: NEW ENGLAND JOURNAL OF MEDICINE
  • Sayfa Sayıları: ss.415-425

Özet

BackgroundRespiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection in infants, and a need exists for prevention of RSV in healthy infants. Nirsevimab is a monoclonal antibody with an extended half-life that is being developed to protect infants for an entire RSV season with a single intramuscular dose.